Corporate Information And Statement Of Ifrs Compliance [Abstract]
| Concept |
2022-01-01 to 2022-12-31 |
As at 2022-12-31 |
As at 2021-12-31 |
|---|---|---|---|
| Corporate information and statement of IFRS compliance [abstract] | |||
| Name of reporting entity or other means of identification |
OSE Immunotherapeutics
|
— | — |
| Legal form of entity |
Société anonyme de droit français à
|
— | — |
| Country of incorporation |
France
|
— | — |
| Principal place of business |
22 boulevard Benoni Goullin, 44200 Nantes
|
— | — |
| Statement of IFRS compliance [text block] |
3.1 Base
|
— | — |
| Disclosure of amounts to be recovered or settled after twelve months for classes of assets and liabilities that contain amounts to be recovered or settled both no more and more than twelve months after reporting date [text block] | — | — | — |
| Disclosure of amounts to be recovered or settled after twelve months for classes of assets and liabilities that contain amounts to be recovered or settled both no more and more than twelve months after reporting date [abstract] | |||
| Disclosure of amounts to be recovered or settled after twelve months for classes of assets and liabilities that contain amounts to be recovered or settled both no more and more than twelve months after reporting date [line items] | |||
| Current trade receivables | — |
403,000
EUR
|
772,000
EUR
|
| Current trade payables | — |
8 539
EUR
|
9 607
EUR
|